What's in Fertility Biotech AG's pipeline?

Fertility Biotech AG has 3 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Fertility Biotech AG's portfolio?

Top competitors by shared drug class: Changchun GeneScience Pharmaceutical Co., Ltd., IVFarma LLC, LG Chem, Merck KGaA, Darmstadt, Germany.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fertility-biotech-ag.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Fertility Biotech AG — Portfolio Competitive Intelligence Brief

Fertility Biotech AG pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Gonal-f® RFF	Gonal-f® RFF	marketed	Gonadotropin; recombinant FSH	FSH receptor (FSHR)	Reproductive Medicine / Fertility
AFOLIA	AFOLIA	phase 3		Folate receptor alpha (FRα)	Fertility / Reproductive Health

Therapeutic area mix

Fertility / Reproductive Health · 1
Reproductive Medicine / Fertility · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Changchun GeneScience Pharmaceutical Co., Ltd. · 1 shared drug class
IVFarma LLC · 1 shared drug class
LG Chem · 1 shared drug class
Merck KGaA, Darmstadt, Germany · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fertility Biotech AG:

Cite this brief

Drug Landscape (2026). Fertility Biotech AG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fertility-biotech-ag. Accessed 2026-05-16.